SCHEMBL25385232

SCHEMBL25385232

COc1ccc(COc2cc(CC(=O)O)ccc2C2OCCO2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 1/20 0.48
▸ AKR1C3 P42330 1/20 0.48
▸ AKR1C2 P52895 1/20 0.48
▸ FFAR1 O14842 2/20 0.45
▸ GAA P10253 2/20 0.45
▸ NFKB1 P19838 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ SLC22A12 Q96S37 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ POLB P06746 2/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.42
▸ RXRA P19793 2/20 0.42
▸ RXRB P28702 2/20 0.42
▸ RXRG P48443 2/20 0.42
▸ LMNA P02545 1/20 0.41
▸ HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30574832 1.00 PTGS1 (0.48) PTGS1AKR1C3AKR1C2FFAR1GAA
SCHEMBL25387769 0.94 PTGS1 (0.47) PTGS1AKR1C3AKR1C2FFAR1GAA
SCHEMBL31562376 0.94 PTGS1 (0.47) PTGS1AKR1C3AKR1C2FFAR1GAA
SCHEMBL25385517 0.90 SMPD1 (0.42) GAAALDH1A1SMN1; SMN2POLBNPC1
SCHEMBL30574783 0.90 SMPD1 (0.42) GAAALDH1A1SMN1; SMN2POLBNPC1
SCHEMBL25385067 0.89 FFAR1 (0.58) FFAR1RXRARXRBRXRG
SCHEMBL31056350 0.87 SMN1; SMN2 (0.55) NFKB1SMN1; SMN2POLBNPC1RAB9A
SCHEMBL31562487 0.87 MEN1 (0.43) GAAALDH1A1TSHRSMN1; SMN2NPC1
SCHEMBL25384316 0.84 PPARG (0.40) AKR1C3AKR1C2FFAR1NFKB1ALDH1A1
SCHEMBL25385031 0.84 LTB4R (0.55) PTGS1AKR1C3AKR1C2FFAR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289789-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2025-09-18 — — US disclosed
WO-2025090658-A2 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2025-05-01 — — WO disclosed
US-20250115600-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2025-04-10 — — US disclosed
EP-4486390-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF Terremoto Biosciences, Inc (US) 2025-01-08 — — EP disclosed
WO-2023168291-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2023-09-07 — — WO disclosed
WO-2023168291-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2023-09-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115600-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF AKT1, AKT1S1, AKT2 PTGS1 3659/4885AKR1C3 3520/4885AKR1C2 3453/4885
US-20250289789-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF CDK2, CDK20, CDK1 PTGS1 2798/4885AKR1C3 1739/4885AKR1C2 1719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback